Active substance
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| NTARIBZ | 150 mg | Capsule, soft · Oral use | 60 Blister | SAR 6833.45 | Generic · Prescription | ALPHA PHARMA INDUSTRY | Valid |
| NTARIBZ | 100 mg | Capsule, soft · Oral use | 60 Blister | SAR 3490.50 | Generic · Prescription | ALPHA PHARMA INDUSTRY | Valid |
| Nintib | 100 mg | Capsule · Oral use | 60 Bottle | SAR 3759.00 | Generic · Prescription | Boston Oncology Arabia | Valid |
| Nintib | 150 mg | Capsule · Oral use | 60 Bottle | SAR 7359.10 | Generic · Prescription | Boston Oncology Arabia | Valid |
| OFEV 100 mg Soft Capsule | 100 mg | Capsule · Oral use | 60 Blister | SAR 5370.35 | NCE · Prescription | BOEHRINGER INGELHEIM | Valid |
| OFEV 150 mg Soft Capsule | 150 mg | Capsule · Oral use | 60 Blister | SAR 10513.00 | NCE · Prescription | BOEHRINGER INGELHEIM | Valid |
Vargatef is indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first line chemotherapy.
Ofev is indicated in adults for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
Nintedanib Accord is indicated in adults for the treatment of idiopathic pulmonary fibrosis (IPF). Nintedanib Accord is also indicated in adults for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (see section 5.1). Nintedanib Accord is indicated in adults for the treatment of systemic sclerosis associated interstitial lung disease (SSc-ILD). Nintedanib Accord is indicated in adults for the treatment of idiopathic pulmonary fibrosis (IPF). Nintedanib Accord is also indicated in adults for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype. Nintedanib Accord is indicated in children and adolescents from 6 to 17 years old for the treatment of clinically significant, progressive fibrosing interstitial lung diseases (ILDs). Nintedanib Accord is indicated in adults, adolescents and children aged 6 years and older for the treatment of systemic sclerosis associated interstitial lung disease (SSc-ILD).
Nintedanib Viatris is indicated in adults for the treatment of idiopathic pulmonary fibrosis (IPF). Nintedanib Viatris is also indicated in adults for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype. Nintedanib Viatris is indicated in children and adolescents from 6 to 17 years old for the treatment of clinically significant, progressive fibrosing interstitial lung diseases (ILDs). Nintedanib Viatris is indicated in adults, adolescents and children aged 6 years and older for the treatment of systemic sclerosis associated interstitial lung disease (SSc-ILD).
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| AURO-NINTEDANIB | 02526891 | 100 MG | CAPSULE · ORAL | AURO PHARMA INC |
| AURO-NINTEDANIB | 02526905 | 150 MG | CAPSULE · ORAL | AURO PHARMA INC |
| JAMP NINTEDANIB | 02540762 | 150 MG | CAPSULE · ORAL | JAMP PHARMA CORPORATION |
| JAMP NINTEDANIB | 02550849 | 100 MG | CAPSULE · ORAL | JAMP PHARMA CORPORATION |
| OFEV | 02443066 | 100 MG | CAPSULE · ORAL | BOEHRINGER INGELHEIM (CANADA) LTD LTEE |
| OFEV | 02443074 | 150 MG | CAPSULE · ORAL | BOEHRINGER INGELHEIM (CANADA) LTD LTEE |
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.